Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Therapie|December 29, 2020
Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)Louise Carton, Mikaïl Nourredine, Benjamin RollandTherapie|January 11, 2021
Towards personalized pharmacology: Antipsychotics and schizophreniaLouise Carton, Régis Bordet, François Montastruc, et al.Current Psychiatry Reports|November 8, 2017
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive DisordersBaptiste Pignon, Chloé Tezenas du Montcel, Louise Carton, et al.Therapie|June 5, 2026
Barriers to prescribing methylphenidate for adults with ADHD: A qualitative studyDiane Lafarge, Joël Charbit, Antoine Lamer, et al.Expert Review of Clinical Pharmacology|August 12, 2022
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinionLouise Carton, Romain Icick, Sébastien Weibel, et al.Journal of Clinical Psychopharmacology|December 19, 2013
Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorderBenjamin Rolland, Emmanuelle Jaillette, Louise Carton, et al.Journal of Neurology|March 24, 2022
Long-term cognitive impairments following COVID-19: a possible impact of hypoxiaThibaut Dondaine, Florine Ruthmann, Fanny Vuotto, et al.Therapie|April 8, 2018
Pharmaceutical cognitive doping in students: A chimeric way to get-a-head?Louise Carton, Nicolas Cabé, Olivier Ménard, et al.Therapie|December 12, 2017
[Pharmaceutical cognitive doping in students: a chimeric way to get-a-head?]Louise Carton, Nicolas Cabé, Olivier Ménard, et al.Therapie|October 11, 2020
TNF-α inhibitors and psychiatric adverse drug reactions in the spectrum of bipolar (manic) or psychotic disorders: Analysis from the French pharmacovigilance databaseCécile Marie Yelnik, Louise Gaboriau, Nadine Petitpain, et al.Pageof 4